SCHEMBL25833427

SCHEMBL25833427

COCCN(C)CC(C)c1cccc(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 2/20 0.49
PIK3CD O00329 1/20 0.45
SLC6A2 P23975 4/20 0.40
SLC6A4 P31645 4/20 0.40
SLC6A3 Q01959 1/20 0.40
HPGD P15428 1/20 0.40
GBA1 P04062 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
KDM4E B2RXH2 3/20 0.38
LMNA P02545 2/20 0.37
HTT P42858 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TAAR1 Q96RJ0 1/20 0.36
MAPK1 P28482 1/20 0.36
TSHR P16473 1/20 0.35
RECQL P46063 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25304003 0.86 AOC3 (0.49) AOC3PIK3CDSLC6A2SLC6A4SLC6A3
SCHEMBL25259270 0.84 MEN1 (0.51) AOC3PIK3CDSLC6A2SLC6A4SLC6A3
SCHEMBL31068788 0.84 MEN1 (0.51) AOC3PIK3CDSLC6A2SLC6A4SLC6A3
SCHEMBL25852918 0.82 PIK3CD (0.44) AOC3PIK3CDSLC6A2SLC6A4SLC6A3
SCHEMBL13974808 0.82 PIK3CD (0.53) AOC3PIK3CDSLC6A2SLC6A4SLC6A3
SCHEMBL25833514 0.80 AOC3 (0.48) AOC3SLC6A2SLC6A4SLC6A3HPGD
SCHEMBL25833347 0.79 AOC3 (0.47) AOC3SLC6A2SLC6A4HPGDGBA1
SCHEMBL17071836 0.78 SLC6A2 (0.51) AOC3SLC6A2SLC6A4SLC6A3HPGD
SCHEMBL16771184 0.78 SLC6A2 (0.51) AOC3SLC6A2SLC6A4SLC6A3HPGD
SCHEMBL25832940 0.78 SLC6A2 (0.51) AOC3SLC6A2SLC6A4SLC6A3HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827637-B2 Azaindole derivatives and their use as ERK kinase inhibitors AGV DISCOVERY (FR) 2023-11-28 US disclosed
US-20230227451-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS AGV DISCOVERY (FR) 2023-07-20 US disclosed
WO-2023135233-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS AGV DISCOVERY (FR) 2023-07-20 WO disclosed
EP-4212531-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS AGV Discovery (FR) 2023-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827637-B2 Azaindole derivatives and their use as ERK kinase inhibitors MAPKAPK2, MAPK1, MAPK7 AOC3 3111/4885PIK3CD 263/4885SLC6A2 1803/4885
US-20230227451-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS MAPKAPK2, MAPK1, MAPK7 AOC3 3111/4885PIK3CD 263/4885SLC6A2 1803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.